AcquisitionOther
Zymeworks Inc. acquired Theravance Biopharma, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Zymeworks Inc. -> Theravance Biopharma, Inc. · $17.00 per share
To add YUPELRI cash flows and strengthen long-term value creation with diversified assets.
Open source record (SEC) ↗